Wafergen Cash Reserves Dwindling as it Preps SmartChip for Market | GenomeWeb

Over the last year, Wafergen has been pumping plenty of cash into R&D and working with several early-access partners to further develop and test its SmartChip real-time PCR system in anticipation of a commercial launch later this year.

But the company faces the prospect that it will run out of cash before it can launch its flagship product, according to a prospectus filed this month with the Securities and Exchange Commission.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?